• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

再灌注后持续酸中毒——肝移植受者 30 天和住院术后死亡率增加的预后指标。

Persistent acidosis after reperfusion-A prognostic indicator of increased 30-day and in-hospital postoperative mortality in liver transplant recipients.

机构信息

Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, New York, New York.

Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Clin Transplant. 2019 Mar;33(3):e13473. doi: 10.1111/ctr.13473. Epub 2019 Jan 24.

DOI:10.1111/ctr.13473
PMID:30597632
Abstract

During liver transplantation, the patient is at risk of developing progressive lactic acidosis. Following reperfusion, correction of acidosis may occur. In some patients, acidosis will worsen, a phenomenon referred to as persistent acidosis after reperfusion (PAAR). We compared postoperative outcomes in patients who manifested PAAR vs those that did not. All adult patients undergoing liver transplantation from 2002 to 2015 were included. PAAR is defined by the presence of a significant negative slope coefficient for base excess values measured after hepatic artery anastomosis through 72 hours postoperatively. Primary outcome was a composite of 30-day and in-hospital mortality. Secondary outcomes included: ICU LOS, total hospital LOS, and re-transplantation rate within 7 days. PAAR occurred in 10% of the transplant recipients. Patients with PAAR had higher MELD, BMI, and eGFR and demonstrated a longer median ICU LOS and hospital median LOS with a trend toward mortality difference. But, after propensity matching, the mortality rate difference became significantly higher in patients with PAAR compared with matched controls while the ICU LOS differences disappeared. The re-transplantation rates were similar also between the PAAR and no PAAR groups. The cohort with PAAR had a significant 30-day and in-hospital increase in mortality after propensity score matching.

摘要

在肝移植过程中,患者存在发生进行性乳酸酸中毒的风险。再灌注后,酸中毒可能得到纠正。在一些患者中,酸中毒会恶化,这种现象称为再灌注后持续性酸中毒(PAAR)。我们比较了表现出 PAAR 和未表现出 PAAR 的患者的术后结局。所有 2002 年至 2015 年期间接受肝移植的成年患者均被纳入研究。PAAR 的定义是术后 72 小时内通过肝动脉吻合术测量的碱剩余值存在显著负斜率系数。主要结局是 30 天和住院内死亡率的复合结局。次要结局包括:ICU 住院时间、总住院时间和 7 天内再次移植率。10%的移植受者出现了 PAAR。PAAR 患者的 MELD、BMI 和 eGFR 更高,ICU 住院时间和医院住院时间中位数更长,且死亡率存在差异的趋势。但经过倾向评分匹配后,PAAR 患者的死亡率明显高于匹配对照组,而 ICU 住院时间的差异则消失。PAAR 和无 PAAR 两组之间的再次移植率也相似。经过倾向评分匹配后,PAAR 组的 30 天和住院内死亡率显著增加。

相似文献

1
Persistent acidosis after reperfusion-A prognostic indicator of increased 30-day and in-hospital postoperative mortality in liver transplant recipients.再灌注后持续酸中毒——肝移植受者 30 天和住院术后死亡率增加的预后指标。
Clin Transplant. 2019 Mar;33(3):e13473. doi: 10.1111/ctr.13473. Epub 2019 Jan 24.
2
The combination of MELD score and ICG liver testing predicts length of stay in the ICU and hospital mortality in liver transplant recipients.终末期肝病模型(MELD)评分与吲哚菁绿(ICG)肝脏检测相结合可预测肝移植受者在重症监护病房(ICU)的住院时间及医院死亡率。
BMC Anesthesiol. 2014 Nov 15;14:103. doi: 10.1186/1471-2253-14-103. eCollection 2014.
3
Liver Transplantation in Recipients With High Model for End-stage Liver Disease Score.终末期肝病模型评分高的受者的肝移植
Transplant Proc. 2018 Mar;50(2):595-597. doi: 10.1016/j.transproceed.2017.12.032.
4
Scoring Systems and Postoperative Outcomes in Pediatric Liver Transplantation.小儿肝移植的评分系统与术后结局
Transplant Proc. 2019 Sep;51(7):2430-2433. doi: 10.1016/j.transproceed.2019.01.174. Epub 2019 Jul 4.
5
Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score ≥ 40: A retrospective cohort study.终末期肝病模型评分≥40 的肝移植受者术后资源利用与生存:一项回顾性队列研究。
Can J Gastroenterol Hepatol. 2015 May;29(4):185-91. doi: 10.1155/2015/954656.
6
Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients.终末期肝病模型(MELD)评分大于 23 预测肝移植受者 ICU 住院时间,但不预测死亡率。
Crit Care. 2010;14(3):R117. doi: 10.1186/cc9068. Epub 2010 Jun 15.
7
Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study.移植前糖尿病对肝移植后短期结局的影响:一项全国队列研究。
Liver Int. 2015 Jul;35(7):1902-9. doi: 10.1111/liv.12770. Epub 2015 Jan 21.
8
A multicenter study of 30 days complications after deceased donor liver transplantation in the model for end-stage liver disease score era.终末期肝病模型评分时代已故供体肝移植术后30天并发症的多中心研究。
Liver Transpl. 2015 Sep;21(9):1160-8. doi: 10.1002/lt.24181.
9
Risk factors and crucial prognostic indicators of mortality in liver transplant recipients with bloodstream infections: A comprehensives study of 1049 consecutive liver transplants over an 11-year period.血流感染的肝移植受者死亡的危险因素和关键预后指标:11 年期间 1049 例连续肝移植的综合研究。
J Microbiol Immunol Infect. 2024 Oct;57(5):771-781. doi: 10.1016/j.jmii.2024.06.002. Epub 2024 Jun 20.
10
The Braden Scale, A standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation.Braden 量表是评估压疮风险的标准工具,可预测肝移植后的早期结局。
Liver Transpl. 2017 Sep;23(9):1153-1160. doi: 10.1002/lt.24789.

引用本文的文献

1
Bicarbonate ringer's solution could improve the intraoperative acid-base equilibrium and reduce hepatocellular enzyme levels after deceased donor liver transplantation: a randomized controlled study.碳酸氢盐林格氏液可改善肝移植术后酸碱平衡并降低肝细胞酶水平:一项随机对照研究。
BMC Anesthesiol. 2023 Dec 19;23(1):418. doi: 10.1186/s12871-023-02383-8.
2
Viscoelastic Management of Coagulopathy during the Perioperative Period of Liver Transplantation.肝移植围手术期凝血功能障碍的黏弹性管理。
Semin Thromb Hemost. 2023 Mar;49(2):119-133. doi: 10.1055/s-0042-1758058. Epub 2022 Nov 1.
3
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation.
酸中毒与肝移植中凝血功能障碍和输血需求的关系。
J Thromb Thrombolysis. 2022 May;53(4):887-897. doi: 10.1007/s11239-021-02609-x. Epub 2021 Nov 20.